Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dose of Surfactant for Preterm Infants with RDS
NCT04984057Unknown
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Biologic
- Countries
- 1
01
Overview
Randomised, open-label trial of bovactant in respiratory distress syndrome (RDS) (2 arms). Primary endpoints: Size of Patent Ductus Arteriosus at 7 days and Incidence of Bronchopulmonary Dysplasia and/or Death. Status: unknown.
02
Drugs
bovactant
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT04984057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984057.